BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vosilasarm readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vosilasarm\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05573126-9119@assetmemo.bio
DTSTAMP:20261121T005444Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Vosilasarm: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Vosilasarm\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/vosilasarm#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/vosilasarm#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
